Maze Therapeutics, Inc. Common Stock (MAZE) — Financial Flexibility Index
Maze Therapeutics, Inc. Common Stock (MAZE) has a Financial Flexibility Index of -0.50x as of March 2026. Free cash flow of $-39.02 Million (operating CF $-39.11 Million minus capex $93.00K) represents -1% of total liabilities ($78.01 Million). Check Maze Therapeutics, Inc. Common Stock PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Maze Therapeutics, Inc. Common Stock Financial Flexibility Index (2022–2025)
Historical Financial Flexibility Index trend for Maze Therapeutics, Inc. Common Stock across 4 annual periods. See Maze Therapeutics, Inc. Common Stock working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Annual Financial Flexibility Index for Maze Therapeutics, Inc. Common Stock (2022–2025)
Year-by-year free cash flow to debt coverage for Maze Therapeutics, Inc. Common Stock. For the full company profile including market capitalisation, see MAZE stock market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -2.64x | $-111.15 Million | $-111.94 Million | $42.16 Million | ▼ -249.2% |
| 2024 | 1.77x | $77.10 Million | $75.95 Million | $43.64 Million | ▲ +225.7% |
| 2023 | -1.41x | $-86.39 Million | $-86.83 Million | $61.45 Million | ▲ +29.9% |
| 2022 | -2.00x | $-97.24 Million | $-99.20 Million | $48.51 Million | — |